Literature DB >> 2748192

The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects.

Geoffrey K Gourlay1, Stefan R Kowalski, John L Plummer, David A Cherry, Philip Gaukroger, Michael J Cousins.   

Abstract

A transdermal formulation of fentanyl (TTS-fentanyl, Alza Corp., Palo Alto, CA) was evaluated in 13 surgical patients after an abdominal operation. An intraoperative dose of fentanyl (100-200 micrograms i.v.) was administered at the same time as the TTS-fentanyl systems (50-125 micrograms/h) were applied to the antero-lateral chest wall. The TTS-fentanyl systems remained in situ for 24 h and were then removed and a second lot of systems were applied to the contra-lateral chest wall. There was a mean (S.D.) delay time of 12.7 (9.6) h before minimum effective blood fentanyl concentrations (MEC) were obtained from the systems and pseudo-steady state was reached between 36 and 48 h. There was a decay time of 16.1 (7.1) h after the systems were removed for the blood fentanyl concentration to decrease to less than the mean MEC for the control of postoperative pain. There was marked variability between patients in the actual hourly fentanyl dose rate determined from the residual amount of fentanyl remaining in the system and the duration of application. Significantly more supplementary pethidine was administered for inadequate postoperative analgesia between 0 and 12 h compared to the 12-24, 24-36 and 36-48 h periods; this was consistent with the observed delay time. Three patients required a reduction in the hourly fentanyl dose rate because of bradypnoea while 1 patient required an increase in dose because of inadequate pain relief. Nausea was the most frequently reported side effect (85% of patients) while bradypnoea, drowsiness, unpleasant dreams and headache were also reported. These effects were due to the combined effects of a sustained blood fentanyl concentration and the intermittent supplementary pethidine doses. Side effects due to the topical formulation were transient and included erythema (8 patients) and a minor rash (2 patients) in the area occluded by the systems. The TTS-fentanyl systems provided a significant contribution to postoperative pain control but, at the TTS dose rates used, supplementary doses of pethidine were required by all patients probably to control 'incident' pain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2748192     DOI: 10.1016/0304-3959(89)90130-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  22 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

2.  ACMT Position Statement: Safety Issues Regarding Prescription Fentanyl Products.

Authors: 
Journal:  J Med Toxicol       Date:  2016-06

Review 3.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

4.  Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers.

Authors:  Hee Youn Choi; Yo Han Kim; Donghyun Hong; Seong Su Kim; Kyun-Seop Bae; Hyeong-Seok Lim
Journal:  Eur J Clin Pharmacol       Date:  2015-05-28       Impact factor: 2.953

5.  ACMT and AACT Position Statement: Preventing Occupational Fentanyl and Fentanyl Analog Exposure to Emergency Responders.

Authors:  Michael J Moss; Brandon J Warrick; Lewis S Nelson; Charles A McKay; Pierre-André Dubé; Sophie Gosselin; Robert B Palmer; Andrew I Stolbach
Journal:  J Med Toxicol       Date:  2017-08-25

6.  Transdermal fentanyl for the treatment of pain after major urological operations. A randomized double-blind comparison with placebo using intravenous patient-controlled analgesia.

Authors:  K A Lehmann; C Einnolf; H J Eberlein; R Nagel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Reduced morphine consumption and pain severity with transdermal fentanyl patches following total knee arthroplasty.

Authors:  Seyyed Mohammad Jalil Abrisham; Rahil Ghahramani; Najmeh Heiranizadeh; Mohammad Kermani-Alghoraishi; Vida Ayatollahi; Hamid Pahlavanhosseini
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-12-02       Impact factor: 4.342

Review 8.  Recent advances in the pharmacological management of pain.

Authors:  Josée Guindon; Jean-Sébastien Walczak; Pierre Beaulieu
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.

Authors:  Carla Ripamonti; Elena Fagnoni; Tiziana Campa; Cinzia Brunelli; Franco De Conno
Journal:  Support Care Cancer       Date:  2006-02-17       Impact factor: 3.603

Review 10.  Transdermal fentanyl: pharmacology and toxicology.

Authors:  Lewis Nelson; Robert Schwaner
Journal:  J Med Toxicol       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.